Cellceutix Corp (CTIX) 1.6200 $CTIX
IMPORTANT SHAREHOLDER ALERT: Wolf Haldenstein Adler Freeman & Herz LLP Announces That a Class Action Lawsuit Has Been Filed Against Cellceutix Corporation in the United States District Court for the Southern District of New York -- CTIX
GlobeNewswire - Fri Oct 02, 7:00PM CDT
Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased or otherwise acquired the securities of Cellceutix Corporation (OTC:CTIX) ("Cellceutix" or the "Company"
securities during the period between May 10, 2013 through August 6, 2015, inclusive (the "Class Period" . Shareholders of Cellceutix Corporation with losses are urged to contact the firm immediately at classmember@whafh.com or (800) 575-0735 or (212) 545-4774.
Cellceutix Retains Ashcroft Law Firm, Seeks Withdrawal of Complaint
Marketwired - Fri Oct 02, 5:19AM CDT
Cellceutix Corporation (OTC: CTIX), issues the following statement in connection with the recent filing of a frivolous and baseless lawsuit in New York:
Enrollment Approximately 50 Percent Complete in Cellceutix Phase 2 Clinical Trial of Prurisol for Chronic Plaque Psoriasis
Marketwired - Wed Sep 30, 8:03AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology and antimicrobial applications, today announces that the Company's Phase 2 clinical trial of the oral drug candidate Prurisol for psoriasis has now enrolled approximately 50 percent of the planned number of patients. The trial was designed to enroll 100 patients with active mild to moderate chronic plaque psoriasis. Enrollment is expected to be completed by the end of 2015.
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Cellceutix Corporation
PR Newswire - Wed Sep 23, 5:12PM CDT
Rigrodsky & Long, P.A.:
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Cellceutix Corporation To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
Business Wire - Wed Sep 23, 2:29PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Cellceutix Corporation (OTC: CTIX) ("Cellceutix" or the "Company" securities during the period between May 10, 2013 through August 6, 2015, inclusive (the "Class Period" . Investors who wish to become proactively involved in the litigation have until November 10, 2015 to seek appointment as lead plaintiff.
Global Autism Pipeline Review, H2 2015 - 19 Companies & 31 Drug Profiles
M2 - Wed Sep 23, 3:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tf7gbm/autism_pipeline) has announced the addition of the "Autism - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Autism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Autism and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Addex Therapeutics Ltd - BioCrea GmbH - BrainStorm Cell Therapeutics Inc. - Cellceutix Corporation - Confluence Pharmaceuticals LLC - Curemark, LLC - Egenix, Inc. - F. Hoffmann-La Roche Ltd. - Heptares Therapeutics Limited - Intra-Cellular Therapies, Inc. - MedDay - Merz Pharma GmbH & Co. KgaA - Mnemosyne Pharmaceuticals, Inc. - Omeros Corporation - Otsuka Holdings Co., Ltd. - Retrophin Inc. - Reviva Pharmaceuticals Inc. - Saniona AB - Sumitomo Dainippon Pharma Co., Ltd. Drug Profiles - (dextromethorphan hydrobromide quinidine sulfate) - acamprosate calcium - ADX-71441 - ADX-88178 - aripiprazole - carbetocin - CM-AT - CN-2097 - Drug for Autism - HTL-14242 - ITI-007 - KM-391 - lurasidone hydrochloride - MD-1103 - memantine hydrochloride - oxytocin - RG-7314 - RO-5285119 - RP-5063 - Small Molecule to Agonize GABAA Receptor Subunit Alpha-5 for Autism - Small Molecule to Modulate GABRA5 Receptor for CNS Disorders - Small Molecule to Target GPR63 for Autism - Small Molecules to Agonize GABAA-Beta 2 Receptor for Epilepsy and Autism - Small Molecules to Antagonize NMDA2A for Central Nervous System Disorders - Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome - Small Molecules to Inhibit Translation Initiation Factor-4E for Cancer and Autism - Small Molecules to Target Oxytocin for Autism and Anxiety Disorders - Stem Cell Therapy for Multiple Sclerosis, Rheumatoid Arthritis, Autism and Bronchopulmonary Dysplasia - Stem Cell Therapy for Neurodegenerative Disorders - suramin hexasodium - VU-0410120 For more information visit http://www.researchandmarkets.com/research/tf...m_pipeline
RTRX: 21.90 (+1.21), ITCI: 43.25 (+3.84), BCLI: 2.32 (+0.10), OMER: 12.29 (+1.12)
Hidradenitis Suppurativa Pipeline Review, H2 2015 - 5 Companies & 7 Drug Profiles
M2 - Tue Sep 22, 10:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jdrmcb/hidradenitis) has announced the addition of the "Hidradenitis Suppurativa - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hidradenitis Suppurativa, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hidradenitis Suppurativa and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Cellceutix Corporation - Delenex Therapeutics AG - Johnson & Johnson - Novartis AG Drug Profiles - adalimumab - adalimumab biosimilar - CJM-112 - DLX-105 - DLX-2751 - Small Molecule to Disrupt Cell Membrane for Hidradenitis Suppurativa - ustekinumab For more information visit http://www.researchandmarkets.com/research/jd...dradenitis
JNJ: 93.93 (+0.76), ABBV: 55.82 (+0.69), NVS: 93.27 (+1.37)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Cellceutix Corporation to Contact Brower Piven Before the Lead Plaintiff Deadline in Class Action Lawsuit - CTIX
GlobeNewswire - Thu Sep 17, 8:10PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Cellceutix Corporation (OTC:CTIX) ("Cellceutix" or the "Company" securities during the period between May 10, 2013 through August 6, 2015, inclusive (the "Class Period" . Investors who wish to become proactively involved in the litigation have until November 10, 2015 to seek appointment as lead plaintiff.
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Cellceutix Corporation.
PR Newswire - Thu Sep 17, 9:00AM CDT
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Cellceutix Corporation ("Cellceutix" or the "Company" (OTC: CTIX -News). Such investors are advised to contact Peretz Bronstein or his investor relations coordinator Eitan Kimelman at info@bgandg.com or 212-697-6484.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellceutix Corporation - CTIX
ACCESSWIRE - Wed Sep 16, 11:24AM CDT
NEW YORK, NY / ACCESSWIRE / September 16, 2015 / Pomerantz LLP is investigating claims on behalf of investors of Cellceutix Corporation ("Cellceutix" or the "Company" (PINKSHEETS: CTIX). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.
Cellceutix Announces Brilacidin Data to Be Presented by ICPD at the Joint 55th Interscience Conference on Antimicrobial Agents & Chemotherapy (ICAAC)
Marketwired - Wed Sep 16, 6:40AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology and antimicrobial applications, is pleased to report that results of its recently completed pharmacokinetic/pharmacodynamic (PK/PD) model entitled "Population Pharmacokinetics (PPK) of Brilacidin (BRI) in Healthy Subjects and Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI)" will be presented as a "poster walk" at the Joint 55th Interscience Conference on Antimicrobial Agents & Chemotherapy and 28th International Congress of Chemotherapy from 12:00 to 2:00 pm PDT on September 18 in San Diego, CA. The oral presentation will be given by the lead author of the poster, Dr. Scott Van Wart, of the Institute for Clinical Pharmacodynamics (ICPD). The poster will be available on the Cellceutix website beginning 12:00 pm PDT Friday, September 18, 2015.
Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Cellceutix Corporation (CTIX)
GlobeNewswire - Tue Sep 15, 6:00PM CDT
Gainey McKenna & Egleston announces that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all persons or entities who purchased the securities of Cellceutix Corporation ("Cellceutix" or the "Company" (OTCMKTS:CTIX) between May 10, 2013 and August 6, 2015, inclusive (the "Class Period" . The Complaint charges the Company and certain of its officers and directors with violations of the federal securities law.
Harwood Feffer LLP Announces Investigation of Cellceutix Corporation
PR Newswire - Tue Sep 15, 2:17PM CDT
Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Cellceutix Corporation ("Cellceutix" or the "Company" (OTC: CTIX), concerning whether the board has breached its fiduciary duties to shareholders.
Robbins Arroyo LLP: Cellceutix Corporation (CTIX) Misled Shareholders According to a Recently Filed Class Action
PR Newswire - Mon Sep 14, 3:40PM CDT
Shareholder rights law firm Robbins Arroyo LLP announces that a securities fraud class action complaint was filed in the U.S. District Court for the Southern District of New York. The complaint alleges that officers and directors of Cellceutix Corporation (OTC: CTIX) violated the Securities Exchange Act of 1934 between May 10, 2013 and August 6, 2015, by making materially false and misleading statements about Cellceutix's business and financial performance. Cellceutix, a clinical stage biopharmaceutical company, engages in discovering and developing small molecule therapies to treat diseases, such as cancer, antibiotics, and inflammatory disease. Its drugs Kevetrin and Brilacidin are currently undergoing clinical studies to treat cancer and bacterial infections, respectively.
Cellceutix Announces Filing of Its Annual Report on Form 10-K
Marketwired - Mon Sep 14, 8:02AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, has filed its Annual Report on Form 10-K for the year ended June 30, 2015 with the Securities and Exchange Commission. A copy of the Annual Report is available to be viewed or downloaded on the Company's website at http://cellceutix.com/corporate/#sthash.ekO240lU.dpbs.
IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces An Investigation Of Claims Against Cellceutix Corporation On Behalf Of Investors
Business Wire - Fri Sep 11, 9:08PM CDT
Goldberg Law PC (http://www.Goldberglawpc.com) announces that it is investigating claims of potential misrepresentations by Cellceutix Corporation ("Cellceutix" or the "Company" (OTC: CTIX). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Cellceutix Corporation - CTIX
Business Wire - Fri Sep 11, 2:37PM CDT
Rosen Law Firm, a global investor rights law firm, announces that it has filed a class action lawsuit on behalf of purchasers of Cellceutix Corporation (OTC: CTIX) securities from May 10, 2013 through August 6, 2015, all dates inclusive (the "Class Period" . The lawsuit seeks to recover damages for Cellceutix investors under the federal securities laws.
Cellceutix to start Phase 2 clinical trial in ovarian cancer upon completion of current cohort in Phase 1 trial
M2 - Wed Sep 09, 3:17AM CDT
Biopharmaceutical company Cellceutix (OtherOTC:CTIX) said on Tuesday it will complete its Phase 1 trial of the novel compound Kevetrin in patients with advanced solid tumors at the completion of the current cohort.
Chronic Plaque Psoriasis Pipeline Review 2015 - 17 Companies & 23 Drug Profiles
M2 - Tue Sep 08, 6:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/clbhgf/chronic_plaque) has announced the addition of the "Chronic Plaque Psoriasis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Plaque Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Plaque Psoriasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbGenomics International, Inc. - Almirall, S.A. - Boehringer Ingelheim GmbH - Cellceutix Corporation - Coherus BioSciences, Inc. - Eli Lilly and Company - GlaxoSmithKline Plc - Johnson & Johnson - Mitsubishi Tanabe Pharma Corporation - Novartis AG - OPKO Health, Inc. - Pfizer Inc. - Sandoz International GmbH - Sun Pharma Advanced Research Company Ltd. - Takeda Pharmaceutical Company Limited - UCB S.A. - XenoPort, Inc. Drug Profiles - AbGn-168H - adalimumab biosimilar - adalimumab biosimilar - baricitinib - BI-655066 - C-82 - certolizumab pegol - CJM-112 - COVA-322 - dimethyl fumarate - etanercept biosimilar - etanercept biosimilar - etanercept biosimilar - GSK-2831781 - ixekizumab - KM-133 - lunacalcipol - MT-1303 - namilumab - orilotimod potassium - tildrakizumab - tofacitinib - XP-23829 For more information visit http://www.researchandmarkets.com/research/cl...nic_plaque
JNJ: 93.93 (+0.76), OPK: 9.10 (+0.62), PFE: 33.08 (+1.24), LLY: 87.52 (+2.34), GSK: 39.50 (+0.76), XNPT: 4.32 (+0.84), NVS: 93.27 (+1.37), CHRS: 20.63 (+1.80)
Cellceutix Plans for Phase 2 Clinical Trial in Ovarian Cancer
Marketwired - Tue Sep 08, 6:01AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that it will be concluding its Phase 1 trial of the novel compound Kevetrin in patients with advanced solid tumors at the completion of the current cohort. The final cohort requires that six patients be treated at the maximum tolerated dose. Three of the six patients in the cohort have already completed the required treatments with Kevetrin. Cellceutix has been advised that the remaining three patients are currently being recruited.
IMPORTANT SHAREHOLDER ALERT: Wolf Haldenstein Adler Freeman & Herz LLP Announces That a Class Action Lawsuit Has Been Filed Against Cellceutix Corporation in the United States District Court for the Southern District of New York -- CTIX
GlobeNewswire - Fri Oct 02, 7:00PM CDT
Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased or otherwise acquired the securities of Cellceutix Corporation (OTC:CTIX) ("Cellceutix" or the "Company"
securities during the period between May 10, 2013 through August 6, 2015, inclusive (the "Class Period" . Shareholders of Cellceutix Corporation with losses are urged to contact the firm immediately at classmember@whafh.com or (800) 575-0735 or (212) 545-4774. Cellceutix Retains Ashcroft Law Firm, Seeks Withdrawal of Complaint
Marketwired - Fri Oct 02, 5:19AM CDT
Cellceutix Corporation (OTC: CTIX), issues the following statement in connection with the recent filing of a frivolous and baseless lawsuit in New York:
Enrollment Approximately 50 Percent Complete in Cellceutix Phase 2 Clinical Trial of Prurisol for Chronic Plaque Psoriasis
Marketwired - Wed Sep 30, 8:03AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology and antimicrobial applications, today announces that the Company's Phase 2 clinical trial of the oral drug candidate Prurisol for psoriasis has now enrolled approximately 50 percent of the planned number of patients. The trial was designed to enroll 100 patients with active mild to moderate chronic plaque psoriasis. Enrollment is expected to be completed by the end of 2015. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Cellceutix Corporation
PR Newswire - Wed Sep 23, 5:12PM CDT
Rigrodsky & Long, P.A.:
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Cellceutix Corporation To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
Business Wire - Wed Sep 23, 2:29PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Cellceutix Corporation (OTC: CTIX) ("Cellceutix" or the "Company"
securities during the period between May 10, 2013 through August 6, 2015, inclusive (the "Class Period" . Investors who wish to become proactively involved in the litigation have until November 10, 2015 to seek appointment as lead plaintiff. Global Autism Pipeline Review, H2 2015 - 19 Companies & 31 Drug Profiles
M2 - Wed Sep 23, 3:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tf7gbm/autism_pipeline) has announced the addition of the "Autism - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Autism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Autism and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Addex Therapeutics Ltd - BioCrea GmbH - BrainStorm Cell Therapeutics Inc. - Cellceutix Corporation - Confluence Pharmaceuticals LLC - Curemark, LLC - Egenix, Inc. - F. Hoffmann-La Roche Ltd. - Heptares Therapeutics Limited - Intra-Cellular Therapies, Inc. - MedDay - Merz Pharma GmbH & Co. KgaA - Mnemosyne Pharmaceuticals, Inc. - Omeros Corporation - Otsuka Holdings Co., Ltd. - Retrophin Inc. - Reviva Pharmaceuticals Inc. - Saniona AB - Sumitomo Dainippon Pharma Co., Ltd. Drug Profiles - (dextromethorphan hydrobromide quinidine sulfate) - acamprosate calcium - ADX-71441 - ADX-88178 - aripiprazole - carbetocin - CM-AT - CN-2097 - Drug for Autism - HTL-14242 - ITI-007 - KM-391 - lurasidone hydrochloride - MD-1103 - memantine hydrochloride - oxytocin - RG-7314 - RO-5285119 - RP-5063 - Small Molecule to Agonize GABAA Receptor Subunit Alpha-5 for Autism - Small Molecule to Modulate GABRA5 Receptor for CNS Disorders - Small Molecule to Target GPR63 for Autism - Small Molecules to Agonize GABAA-Beta 2 Receptor for Epilepsy and Autism - Small Molecules to Antagonize NMDA2A for Central Nervous System Disorders - Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome - Small Molecules to Inhibit Translation Initiation Factor-4E for Cancer and Autism - Small Molecules to Target Oxytocin for Autism and Anxiety Disorders - Stem Cell Therapy for Multiple Sclerosis, Rheumatoid Arthritis, Autism and Bronchopulmonary Dysplasia - Stem Cell Therapy for Neurodegenerative Disorders - suramin hexasodium - VU-0410120 For more information visit http://www.researchandmarkets.com/research/tf...m_pipeline
RTRX: 21.90 (+1.21), ITCI: 43.25 (+3.84), BCLI: 2.32 (+0.10), OMER: 12.29 (+1.12)
Hidradenitis Suppurativa Pipeline Review, H2 2015 - 5 Companies & 7 Drug Profiles
M2 - Tue Sep 22, 10:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jdrmcb/hidradenitis) has announced the addition of the "Hidradenitis Suppurativa - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hidradenitis Suppurativa, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hidradenitis Suppurativa and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Cellceutix Corporation - Delenex Therapeutics AG - Johnson & Johnson - Novartis AG Drug Profiles - adalimumab - adalimumab biosimilar - CJM-112 - DLX-105 - DLX-2751 - Small Molecule to Disrupt Cell Membrane for Hidradenitis Suppurativa - ustekinumab For more information visit http://www.researchandmarkets.com/research/jd...dradenitis
JNJ: 93.93 (+0.76), ABBV: 55.82 (+0.69), NVS: 93.27 (+1.37)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Cellceutix Corporation to Contact Brower Piven Before the Lead Plaintiff Deadline in Class Action Lawsuit - CTIX
GlobeNewswire - Thu Sep 17, 8:10PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Cellceutix Corporation (OTC:CTIX) ("Cellceutix" or the "Company"
securities during the period between May 10, 2013 through August 6, 2015, inclusive (the "Class Period" . Investors who wish to become proactively involved in the litigation have until November 10, 2015 to seek appointment as lead plaintiff. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Cellceutix Corporation.
PR Newswire - Thu Sep 17, 9:00AM CDT
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Cellceutix Corporation ("Cellceutix" or the "Company"
(OTC: CTIX -News). Such investors are advised to contact Peretz Bronstein or his investor relations coordinator Eitan Kimelman at info@bgandg.com or 212-697-6484. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellceutix Corporation - CTIX
ACCESSWIRE - Wed Sep 16, 11:24AM CDT
NEW YORK, NY / ACCESSWIRE / September 16, 2015 / Pomerantz LLP is investigating claims on behalf of investors of Cellceutix Corporation ("Cellceutix" or the "Company"
(PINKSHEETS: CTIX). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980. Cellceutix Announces Brilacidin Data to Be Presented by ICPD at the Joint 55th Interscience Conference on Antimicrobial Agents & Chemotherapy (ICAAC)
Marketwired - Wed Sep 16, 6:40AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology and antimicrobial applications, is pleased to report that results of its recently completed pharmacokinetic/pharmacodynamic (PK/PD) model entitled "Population Pharmacokinetics (PPK) of Brilacidin (BRI) in Healthy Subjects and Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI)" will be presented as a "poster walk" at the Joint 55th Interscience Conference on Antimicrobial Agents & Chemotherapy and 28th International Congress of Chemotherapy from 12:00 to 2:00 pm PDT on September 18 in San Diego, CA. The oral presentation will be given by the lead author of the poster, Dr. Scott Van Wart, of the Institute for Clinical Pharmacodynamics (ICPD). The poster will be available on the Cellceutix website beginning 12:00 pm PDT Friday, September 18, 2015. Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Cellceutix Corporation (CTIX)
GlobeNewswire - Tue Sep 15, 6:00PM CDT
Gainey McKenna & Egleston announces that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all persons or entities who purchased the securities of Cellceutix Corporation ("Cellceutix" or the "Company"
(OTCMKTS:CTIX) between May 10, 2013 and August 6, 2015, inclusive (the "Class Period" . The Complaint charges the Company and certain of its officers and directors with violations of the federal securities law. Harwood Feffer LLP Announces Investigation of Cellceutix Corporation
PR Newswire - Tue Sep 15, 2:17PM CDT
Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Cellceutix Corporation ("Cellceutix" or the "Company"
(OTC: CTIX), concerning whether the board has breached its fiduciary duties to shareholders. Robbins Arroyo LLP: Cellceutix Corporation (CTIX) Misled Shareholders According to a Recently Filed Class Action
PR Newswire - Mon Sep 14, 3:40PM CDT
Shareholder rights law firm Robbins Arroyo LLP announces that a securities fraud class action complaint was filed in the U.S. District Court for the Southern District of New York. The complaint alleges that officers and directors of Cellceutix Corporation (OTC: CTIX) violated the Securities Exchange Act of 1934 between May 10, 2013 and August 6, 2015, by making materially false and misleading statements about Cellceutix's business and financial performance. Cellceutix, a clinical stage biopharmaceutical company, engages in discovering and developing small molecule therapies to treat diseases, such as cancer, antibiotics, and inflammatory disease. Its drugs Kevetrin and Brilacidin are currently undergoing clinical studies to treat cancer and bacterial infections, respectively.
Cellceutix Announces Filing of Its Annual Report on Form 10-K
Marketwired - Mon Sep 14, 8:02AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, has filed its Annual Report on Form 10-K for the year ended June 30, 2015 with the Securities and Exchange Commission. A copy of the Annual Report is available to be viewed or downloaded on the Company's website at http://cellceutix.com/corporate/#sthash.ekO240lU.dpbs. IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces An Investigation Of Claims Against Cellceutix Corporation On Behalf Of Investors
Business Wire - Fri Sep 11, 9:08PM CDT
Goldberg Law PC (http://www.Goldberglawpc.com) announces that it is investigating claims of potential misrepresentations by Cellceutix Corporation ("Cellceutix" or the "Company"
(OTC: CTIX). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors. EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Cellceutix Corporation - CTIX
Business Wire - Fri Sep 11, 2:37PM CDT
Rosen Law Firm, a global investor rights law firm, announces that it has filed a class action lawsuit on behalf of purchasers of Cellceutix Corporation (OTC: CTIX) securities from May 10, 2013 through August 6, 2015, all dates inclusive (the "Class Period"
. The lawsuit seeks to recover damages for Cellceutix investors under the federal securities laws. Cellceutix to start Phase 2 clinical trial in ovarian cancer upon completion of current cohort in Phase 1 trial
M2 - Wed Sep 09, 3:17AM CDT
Biopharmaceutical company Cellceutix (OtherOTC:CTIX) said on Tuesday it will complete its Phase 1 trial of the novel compound Kevetrin in patients with advanced solid tumors at the completion of the current cohort.
Chronic Plaque Psoriasis Pipeline Review 2015 - 17 Companies & 23 Drug Profiles
M2 - Tue Sep 08, 6:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/clbhgf/chronic_plaque) has announced the addition of the "Chronic Plaque Psoriasis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Plaque Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Plaque Psoriasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbGenomics International, Inc. - Almirall, S.A. - Boehringer Ingelheim GmbH - Cellceutix Corporation - Coherus BioSciences, Inc. - Eli Lilly and Company - GlaxoSmithKline Plc - Johnson & Johnson - Mitsubishi Tanabe Pharma Corporation - Novartis AG - OPKO Health, Inc. - Pfizer Inc. - Sandoz International GmbH - Sun Pharma Advanced Research Company Ltd. - Takeda Pharmaceutical Company Limited - UCB S.A. - XenoPort, Inc. Drug Profiles - AbGn-168H - adalimumab biosimilar - adalimumab biosimilar - baricitinib - BI-655066 - C-82 - certolizumab pegol - CJM-112 - COVA-322 - dimethyl fumarate - etanercept biosimilar - etanercept biosimilar - etanercept biosimilar - GSK-2831781 - ixekizumab - KM-133 - lunacalcipol - MT-1303 - namilumab - orilotimod potassium - tildrakizumab - tofacitinib - XP-23829 For more information visit http://www.researchandmarkets.com/research/cl...nic_plaque
JNJ: 93.93 (+0.76), OPK: 9.10 (+0.62), PFE: 33.08 (+1.24), LLY: 87.52 (+2.34), GSK: 39.50 (+0.76), XNPT: 4.32 (+0.84), NVS: 93.27 (+1.37), CHRS: 20.63 (+1.80)
Cellceutix Plans for Phase 2 Clinical Trial in Ovarian Cancer
Marketwired - Tue Sep 08, 6:01AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that it will be concluding its Phase 1 trial of the novel compound Kevetrin in patients with advanced solid tumors at the completion of the current cohort. The final cohort requires that six patients be treated at the maximum tolerated dose. Three of the six patients in the cohort have already completed the required treatments with Kevetrin. Cellceutix has been advised that the remaining three patients are currently being recruited. 
